Quick Facts
Plain-English Summary
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| High-fat diet (HFD) mice — insulin sensitivity | Intraperitoneal MOTS-C injection significantly improved insulin tolerance and reduced fasting blood glucose compared to vehicle-treated HFD controls. AMPK activation confirmed in skeletal muscle. Lee et al., Cell Metabolism 2015 ↗ | Preclinical |
| Exercise endurance — mice | MOTS-C-treated mice showed improved treadmill endurance and enhanced mitochondrial oxidative capacity in skeletal muscle. Proposed mechanism: AMPK-mediated metabolic reprogramming. Kim SJ et al. 2018 ↗ | Preclinical |
| Aged mouse lifespan model | Repeated MOTS-C administration to aged C57BL/6 mice extended median lifespan and improved physical performance. Improvement in inflammatory markers also reported. One study; not independently replicated as of 2026. Kim SJ et al. 2021 ↗ | Preclinical |
| Ovariectomised mouse — metabolic model | MOTS-C reversed metabolic dysfunction and weight gain in surgically menopausal mice, suggesting relevance to age-related hormonal metabolic changes. Zempo H et al. 2021 ↗ | Preclinical |
| In vitro — skeletal muscle cells | Direct MOTS-C treatment of C2C12 myotubes activated AMPK, increased glucose oxidation, and upregulated mitochondrial biogenesis markers. Effects blocked by AMPK inhibitor compound C, confirming AMPK-dependence. | In Vitro |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Observational — plasma MOTS-C & metabolic health | Cross-sectional analysis correlating circulating MOTS-C levels with insulin sensitivity, BMI, and age in healthy adults. No intervention; no control group. Lee et al. 2015 ↗ | — | Correlational |
| Observational — exercise-induced MOTS-C elevation | Small cohort study demonstrating acute rise in plasma MOTS-C following exercise in healthy human subjects. Confirms endogenous peptide is exercise-responsive in humans. No intervention arm. | — | Correlational |
| Interventional trials — all indications | — | — | No Data |
MOTS-C has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No significant toxicity has been reported in rodent studies at doses used in efficacy experiments. However, the preclinical safety database for MOTS-C is very thin compared to compounds with longer research histories. Absence of reported toxicity in a small number of animal studies is not equivalent to a confirmed safety profile.
There is no published human pharmacokinetic data, no Phase I dose-escalation study, and no adverse event registry for MOTS-C. The compound's behaviour after exogenous subcutaneous injection in humans — including absorption, distribution, metabolism, and elimination — is entirely unknown. Any dosing protocol circulating in self-experimentation communities is without scientific basis.
- AMPK activation at supraphysiological levels could suppress mTOR and interfere with protein synthesis
- Immune response to exogenous peptide administration (immunogenicity) unstudied
- Long-term effects of elevated AMPK activity on cardiac or skeletal muscle not characterised
- Nuclear translocation and gene regulation effects at non-physiological doses unknown
- Active or suspected malignancy
- Pregnancy or breastfeeding
- Type 1 diabetes or insulin-dependent diabetes
- Immunocompromised status
- Concurrent use of glucose-lowering medications (hypoglycaemia risk theoretical)
- Children and adolescents
MOTS-C is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of MOTS-C for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The 2015 Lee paper is genuinely one of the more surprising findings in recent cell biology. The idea that a functional signalling peptide is being produced inside the mitochondria and exported — not imported — just wasn't in the conceptual toolkit before that. The canonical model was: nucleus encodes everything important, mitochondria receive instructions. MOTS-C inverts part of that story. Whether it has therapeutic relevance in humans is a separate and very open question, but the discovery itself is real and well-documented.
The AMPK activation piece is pharmacologically coherent and the downstream effects on GLUT4 translocation are well-supported in the in vitro data. My concern is that exogenous administration is a completely different context from endogenous signalling. The physiological concentration, pulsatility, and spatial distribution of endogenous MOTS-C are all unknown. Injecting a synthetic version at some arbitrary dose is a long way from recapitulating what the mitochondria actually do with this molecule.
The lifespan extension data in aged mice is getting heavily quoted in longevity circles but there's an important caveat nobody mentions: it's one study, the effect size in actual lifespan terms is moderate, and we have no idea what the mechanism is specifically — "reduced inflammation" is not a mechanism. The exercise-induced rise in human plasma MOTS-C is much more credible because it's a simple observational measurement, not a claim about intervention effect. Those two categories of evidence are very different and people conflate them constantly.
The dosing protocols being shared online are essentially invented. There is no published human PK for MOTS-C — we do not know its half-life after subcutaneous injection, its volume of distribution, its renal clearance rate, or whether it reaches target tissues at all after peripheral injection. The rodent studies use intraperitoneal administration which is not comparable to subcutaneous. The people injecting 5 mg or 10 mg are making a bet with no pharmacological basis. That doesn't mean it's dangerous — we genuinely don't know — but the confidence with which dosing advice is given in this community is completely unwarranted.
This is the honest state of it. The discovery science is real and genuinely exciting. The translational gap is real and genuinely large. Anybody who tells you these two things are close together is not being straight with you.
From a clinical perspective, the most interesting aspect isn't the exogenous compound — it's the endogenous decline story. If MOTS-C levels fall predictably with age and metabolic dysfunction, and if they rise with exercise, then MOTS-C is potentially a biomarker and a mechanism linking physical activity to metabolic health. That's independent of whether injecting synthetic MOTS-C does anything useful. The research group at USC is doing legitimate science; the community around it is running well ahead of the data.